PDE4A and chronic obstructive pulmonary disease: In this study, we sought to assess the therapeutic potential of roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor currently approved for the treatment of chronic obstructive pulmonary disease (COPD) [12].